Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures
暂无分享,去创建一个
J. M. Bradshaw | April Wong | Jim W Barnett | A. Kuglstatter | D. Shaw | S. Tsing | J. Barnett | M. Browner | Andreas Kuglstatter | A. Villaseñor | Armando G Villaseñor | J Michael Bradshaw | J. Bradshaw | A. Wong | Simon W Lee | Michelle F Browner | David Shaw | Stan Tsing | Yan Lou | Yan Lou | Simon W. Lee | A. Villaseñor
[1] P. Caron,et al. Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.
[2] J. M. Bradshaw,et al. Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase* , 2007, Journal of Biological Chemistry.
[3] A. Kuglstatter,et al. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. , 2010, Journal of medicinal chemistry.
[4] L. Silvian,et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.
[5] F. Uckun,et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* , 1999, The Journal of Biological Chemistry.
[6] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .
[7] Jim W Barnett,et al. Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes , 2009, Chemical biology & drug design.
[8] F. Uckun,et al. Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.
[9] A. Kuglstatter,et al. Crystal Structures of IL‐2‐inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation , 2010, Chemical biology & drug design.
[10] F. Uckun,et al. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity , 2010, Expert opinion on therapeutic patents.
[11] Paul R. Gerber,et al. Peptide mechanics: A force field for peptides and proteins working with entire residues as smallest units , 1992 .
[12] T. Wirth,et al. Bruton's Tyrosine Kinase is involved in innate and adaptive immunity. , 2005, Histology and histopathology.
[13] D. Fabbro,et al. Structural biology contributions to tyrosine kinase drug discovery. , 2009, Current opinion in cell biology.
[14] Jessica M. Lindvall,et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling , 2005, Immunological reviews.
[15] Z. Pan. Bruton's tyrosine kinase as a drug discovery target. , 2008, Drug news & perspectives.
[16] D. Rotstein,et al. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. , 2006, Journal of medicinal chemistry.
[17] O. Witte,et al. Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. , 2006, International immunology.
[18] D. Payan,et al. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[19] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[20] M. Genovese,et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.
[21] Robert M. Sweet,et al. Macromolecular Crystallography: Part A , 1997 .
[22] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[23] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[24] P. Norman. A novel Syk kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011 , 2009, Expert opinion on therapeutic patents.
[25] C. Toniolo,et al. The polypeptide 310-helix. , 1991, Trends in biochemical sciences.